Corcept Therapeutics is a biopharmaceutical company focused on medicines that modulate the effects of the stress hormone cortisol. Its commercial product Korlym (mifepristone) treats hyperglycemia secondary to hypercortisolism in adults with Cushing’s syndrome. The pipeline centers on next-generation selective cortisol modulators for endocrine, metabolic, and oncology indications. The business model is specialty pharma: concentrated R&D and commercialization around a single hormone pathway.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 194.4 | — | 34.6 | 3.9% |
| Q3 2025 | 207.6 | — | 19.4 | -54.8% |
| Q4 2025 | 202.1 | — | 23.9 | -12.3% |
| Q1 2026 | 164.9 | — | -31.2 | -274% |
| Q2 2026 | 256.1 | 31.7% | 42.1 | 21.8% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Maplebear Inc. (CART), Gaming and Leisure Properties, Inc. (GLPI), Tempus AI, Inc. (TEM), Summit Therapeutics Inc. (SMMT), Freedom Holdings Corp. (FRHC), Bio-Techne Corporation (TECH)